Organization
NYU Medical Center-Perlmutter Cancer Center
5 abstracts
Abstract
A phase 1/2 dose escalation and expansion study of sonodynamic therapy with SONALA-001 in combination with Exablate 4000 Type 2.0 MR-guided focused ultrasound in patients with progressive or recurrent glioblastoma (rGBM).Org: NYU Medical Center-Perlmutter Cancer Center,
Abstract
Long-term outcomes of pembrolizumab (pembro) in combination with gemcitabine (gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIUC): A multicenter phase 2 trial.Org: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, University of Chicago Comprehensive Cancer Center, Chicago, IL, University of Michigan Rogel Comprehensive Cancer Center, Memorial Sloan Kettering Cancer Center, Lineberger Comprehensive Cancer Center,
Abstract
A theranostic approach: Imaging and therapy of delta-like ligand 3–expressing small cell lung cancers.Org: Memorial Sloan Kettering Cancer Center, NYU Medical Center-Perlmutter Cancer Center,
Abstract
Technology-enhanced acceleration of germline evaluation for therapy (TARGET): Results of a randomized controlled trial of a pretest patient-driven webtool vs. genetic counseling for prostate cancer germline testing.Org: Yale Cancer Center, Yale School of Medicine, New Haven, CT, Yale School of Medicine, Division of Biostatistics, Department of Data Science, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, Department of Pharmacology & Experimental Therapeutics, Thomas Jefferson University,
Abstract
Distinct genetic and phenotypic characteristics of not otherwise specified (NOS) melanoma.Org: NYU Langone Health, New York, NY, Laura and Isaac Perlmutter Cancer Center, NYU School of Medicine, New York University School of Medicine, NYU Medical Center-Perlmutter Cancer Center,